logo
Plus   Neg
Share
Email

FDA Grants Priority Review For Novartis' Sickle Cell Medicine Crizanlizumab

Novartis (NVS) said Tuesday that the US Food and Drug Administration accepted the company's Biologics License Application or BLA and granted Priority Review for its investigational sickle cell medicine crizanlizumab or SEG101.

If FDA-approved, crizanlizumab is expected to represent the first monoclonal antibody targeting the P-selectin mediated multi-cellular adhesion in sickle cell disease.

Sickle cell disease is a debilitating inherited genetic blood disorder that affects the shape of the red blood cells and can make blood cells and blood vessels stickier than usual.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Southwire Co. LLC recalled about 3000 units of Garvin pop-up electrical outlet floor box kits for concerns of fire hazard. The company said the electrical receptacles can overheat when in use. Southwire already received three reports of the floor boxes overheating. However, there have been no injuries reported so far. The Pentagon has canceled a billion dollar contract with Boeing Co. for a new ballistic missile interceptor due to technical design problems. The contract was for developing the Redesigned Kill Vehicle or RKV, intended to intercept and shoot down current and future-generation incoming ballistic missiles from North Korea and Iran at extremely high altitudes. While reporting financial results for the third quarter on Thursday, branded food company Hormel Foods Corp. (HRL) reaffirms its earnings guidance for the full-year 2019, while trimming annual net sales outlook as its navigates near-term uncertainty related to African swine fever. For fiscal 2019,...
Follow RTT